privately funded plans may also use cadth or inesss’ recommendations to decide whether or not to add the medication to their formularies, but they are not required to do so.
who decides whether my drug is included in a formulary?
cadth and inesss make recommendations for coverage for publicly funded plans, but the final decision on whether the drug will be included on the formulary is made by each individual province. similarly, insurance companies typically decide which drugs are included on their formularies.
some formularies are “open” formularies, meaning that every drug is included, no matter how well it works and how much it costs.
what do pharmaceutical companies have to do with drug pricing?
when pharmaceutical companies develop a drug, they must apply to health canada to get the drug approved for sale in canada — this involves a detailed review of all clinical trials and other data related to the drug. once health canada confirms that the drug is safe and effective, it provides a notice of compliance (noc) and pharmaceutical companies must then apply for funding from public and private drug plans.
how are drug prices determined?
pharmaceutical companies determine the manufacturer list price (mlp) for each drug. some public and private plans negotiate a price reduction when deciding whether to include the drug in their formulary.
the pan-canadian pharmaceutical alliance (pcpa) is a negotiating organization for public plans only — that is, for all provinces, territories, and some federal organizations. before a drug is covered by a publicly funded plan, pcpa is almost always involved. it aims to negotiate lower prices for public plans, by way of a confidential discount. private insurance companies are not included in these negotiations, therefore their pricing is typically higher. some private plans negotiate lower prices on their own.